Weirong Wang

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
    Weirong Wang
    Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Biopharm Drug Dispos 31:253-63. 2010
  2. doi Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences
    Weirong Wang
    Department of Drug Metabolism and Pharmacokinetics, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Drug Metab Dispos 39:1469-77. 2011
  3. doi The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris
    Liming Liu
    Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
    Pharm Res 30:803-12. 2013
  4. doi Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
    Weirong Wang
    Preclinical DMPK Department, Merck Research Laboratories, Merck Sharp and Dohme Corp, West Point, PA 19486, United States
    Mol Immunol 48:860-6. 2011
  5. doi Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials
    Liming Liu
    Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, West Point, PA 19486, USA
    Biologicals 39:205-10. 2011
  6. pmc A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
    Yan G Ni
    Department of Cardiovascular Diseases, Merck Research Laboratories, Rahway, New Jersey, USA
    J Lipid Res 52:78-86. 2011
  7. doi Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs
    Weirong Wang
    Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Drug Metab Dispos 40:952-62. 2012

Detail Information

Publications7

  1. doi Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
    Weirong Wang
    Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Biopharm Drug Dispos 31:253-63. 2010
    ....
  2. doi Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences
    Weirong Wang
    Department of Drug Metabolism and Pharmacokinetics, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Drug Metab Dispos 39:1469-77. 2011
    ....
  3. doi The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris
    Liming Liu
    Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
    Pharm Res 30:803-12. 2013
    ..Our objective was to investigate the correlation between sialic acid content and pharmacokinetic properties of recombinant TNFR2:Fc fusion proteins generated in glycoengineered P. pastoris strains...
  4. doi Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
    Weirong Wang
    Preclinical DMPK Department, Merck Research Laboratories, Merck Sharp and Dohme Corp, West Point, PA 19486, United States
    Mol Immunol 48:860-6. 2011
    ..The relatively low levels of Met oxidation accumulated during 3 years of refrigerated storage had minimal impact on FcRn binding and no detectable impact on the serum half-life...
  5. doi Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials
    Liming Liu
    Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, West Point, PA 19486, USA
    Biologicals 39:205-10. 2011
    ..These results suggest the potential application of P. pastoris as a production platform for clinically viable mAbs...
  6. pmc A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
    Yan G Ni
    Department of Cardiovascular Diseases, Merck Research Laboratories, Rahway, New Jersey, USA
    J Lipid Res 52:78-86. 2011
    ..Together these results clearly demonstrate that the LDL-lowering effect of the neutralizing anti-PCSK9 1D05-IgG2 antibody is mediated by reducing the amount of PCSK9 that can bind to the LDLr...
  7. doi Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs
    Weirong Wang
    Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Sharp and Dohme Corp, West Point, PA 19486, USA
    Drug Metab Dispos 40:952-62. 2012
    ..g., rats and dogs, and that mechanistic understanding of the subcutaneous absorption mechanism and associated determinants should be helpful in biologic drug discovery and development...